Piramal Pharma’s contract development and manufacturing organisation (CDMO) business declined by 6% from last year to ₹997 crore from ₹1,057 crore. It was impacted by destocking in one large on-patent commercial product.
Piramal Pharma’s contract development and manufacturing organisation (CDMO) business declined by 6% from last year to ₹997 crore from ₹1,057 crore. It was impacted by destocking in one large on-patent commercial product.